Dan Ireland - Exscientia Executive Secretary
EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Executive
Dan Ireland is Executive Secretary of Exscientia Ltd ADR
Phone | 44 18 6581 8941 |
Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
Maria Kelman | Pieris Pharmaceuticals | N/A | |
Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
Xiaolin Wang | Revolution Medicines | 53 | |
XiaoJian Zhou | Atea Pharmaceuticals | N/A | |
Gregory Conn | PDS Biotechnology Corp | 69 | |
Gary Whale | Zura Bio Limited | 50 | |
Nick MD | Century Therapeutics | N/A | |
Frank Vollmering | Pieris Pharmaceuticals | N/A | |
Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
Jayanthi Wolf | Atea Pharmaceuticals | N/A | |
Jason Baum | Leap Therapeutics | 45 | |
Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
JD Esq | Kymera Therapeutics | 65 | |
Wayne CPA | Atea Pharmaceuticals | 55 | |
Edmund Dunn | Monte Rosa Therapeutics | 58 | |
Cynthia MD | Leap Therapeutics | 54 | |
Candice Masse | Elevation Oncology | N/A | |
Kevin Leggat | Recursion Pharmaceuticals | N/A | |
Matthew Kinn | Recursion Pharmaceuticals | N/A | |
Deborah MBA | Relay Therapeutics | N/A |
Management Performance
Return On Equity | -0.46 | ||||
Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Overington, Chief Officer | ||
Eileen JenningsBrown, Chief Officer | ||
Ben AshwellFryer, VP Fin | ||
Parker Moss, Executive Development | ||
Ben Taylor, Chief CFO | ||
CBE DPHIL, CEO Founder | ||
Nikolaus Krall, Executive Medicine | ||
Dan Ireland, Executive Secretary | ||
Heather Togwell, Operations Mang | ||
Caroline Rowland, Chief Officer | ||
Chris Thomas, VP People | ||
Garry Pairaudeau, Chief Officer | ||
MarieLouise MD, Interim Lead | ||
FRSE DPHIL, CEO Founder | ||
David Hallett, Interim Officer | ||
Michael MD, Chief Officer | ||
Margo Mosley, VP Operations | ||
Richard Law, Chief Officer | ||
Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.46 | ||||
Return On Asset | -0.21 | ||||
Operating Margin | (10.66) % | ||||
Current Valuation | 346.92 M | ||||
Shares Outstanding | 130.82 M | ||||
Shares Owned By Insiders | 25.90 % | ||||
Shares Owned By Institutions | 20.80 % | ||||
Number Of Shares Shorted | 2.81 M | ||||
Price To Book | 1.95 X | ||||
Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exscientia Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |